- Conditions
- Renal Cell Carcinoma
- Interventions
- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab
- Biological
- Lead sponsor
- SillaJen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 5
- States / cities
- Irvine, California • Miami, Florida • St Louis, Missouri + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 937–960
of 17,835
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Nausea, Vomiting
- Interventions
- aprepitant, Ondansetron
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Winston-Salem, North Carolina • Burlington, Vermont
- Conditions
- Acute Myeloid Leukemia, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
- Interventions
- LNK01002
- Drug
- Lead sponsor
- Lynk Pharmaceuticals Co., Ltd
- Industry
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Farmington Hills, Michigan • Sterling Heights, Michigan
- Conditions
- HIV Infections
- Interventions
- Placebo, Aprepitant
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Bone marrow transplantation, Cytoxan, testosterone cypionate
- Procedure · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
- Interventions
- GSK189075
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- LGMD2I
- Interventions
- PF 06252616
- Drug
- Lead sponsor
- Kathryn Wagner
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diffuse Large B-Cell Lymphoma, Lymphoma, Diffuse Large-Cell, Diffuse Large-Cell Lymphoma, Lymphoma
- Interventions
- Bendamustine, Rituximab
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 7
- States / cities
- Boone, North Carolina • Chapel Hill, North Carolina • Concord, North Carolina + 4 more
- Conditions
- Hepatocellular Carcinoma, HCC
- Interventions
- Nivolumab, Ipilimumab, Cabozantinib, Transarterial Chemoembolization
- Drug · Procedure
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Fabry Disease
- Interventions
- migalastat HCl
- Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Decatur, Georgia • Bethesda, Maryland + 2 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- LY3471851, Placebo
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • La Jolla, California • Clearwater, Florida + 11 more
- Conditions
- IPEX
- Interventions
- CD4^LVFOXP3
- Biological
- Lead sponsor
- Bacchetta, Rosa, MD
- Other
- Eligibility
- 4 Months to 35 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Coronary Heart Disease
- Interventions
- DFV890, DFV890 Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- Northridge, California • Boca Raton, Florida • Jacksonville, Florida + 3 more
- Conditions
- Refractory Generalized Myasthenia Gravis
- Interventions
- Eculizumab, Placebo
- Biological · Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Fresno, California • Los Angeles, California + 35 more
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Atezolizumab Placebo, Paclitaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 653 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 8
- States / cities
- Stanford, California • Fort Myers, Florida • St. Petersburg, Florida + 5 more
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Interventions
- Lenalidomide, Velcade
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Myeloid Leukemia
- Interventions
- PF-06747143, Cytarabine, Daunorubicin, Azacitidine, Decitabine
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Chicago, Illinois • Winston-Salem, North Carolina
- Conditions
- Cancer
- Interventions
- E7389
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Santa Monica, California • New Brunswick, New Jersey
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration, Resection, Temozolomide, Triapine
- Procedure · Other · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy
- Interventions
- Alprazolam Extended-Release 3 mg Tablets
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 2
- States / cities
- East Grand Forks, Minnesota • Fargo, North Dakota
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- PBCAR269A, Fludarabine, Cyclophosphamide, Nirogacestat
- Genetic · Drug
- Lead sponsor
- Precision BioSciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Duarte, California • San Francisco, California • Boston, Massachusetts + 2 more
- Conditions
- Healthy
- Interventions
- dolutegravir
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Healthy Participants
- Interventions
- PF-06651600
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Hollywood, Florida • Saint Paul, Minnesota
- Conditions
- Renal Cell Carcinoma
- Interventions
- CTT1057
- Drug
- Lead sponsor
- Cancer Targeted Technology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California